Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Mesalazine [5-aminosalicylic acid (5-ASA)] has been used for over 30 years in the treatment of inflammatory bowel disease (IBD). It is a highly effective, safe, and well-tolerated drug for treatment of mild to moderate ulcerative colitis, which represents most patients with this disease. Recent studies of patient adherence to 5-ASA therapies in ulcerative colitis have highlighted the need for regimens that enable long-term compliance to significantly reduce the risk of troublesome and debilitating flares in the short term, and possibly colon cancer in the long term. Indeed, much of the recent innovation in clinical use of 5-ASA in colitis has come from studies of novel delivery mechanisms and simplified oral dosing schedules. These studies have provided much needed clarity on essential matters such as starting dose, dose escalation, and efficacy in terms of the ideal clinical endpoint - mucosal healing. Various manufacturers are re-evaluating their products to determine the safety and efficacy of such dosing regimens. Although once widely employed in the treatment of Crohn’s disease (CD), the accumulated body of evidence now suggests that there is a much more limited role for 5-ASA in this particular form of inflammatory bowel disease. Recent 5-ASA randomized-controlled trials, comparative studies, and outcomes research have led to refined treatment strategies and awareness for practitioners to better inform, engage and facilitate patients in optimal use of 5-ASA in inflammatory bowel disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb
Jiang, J., & Struhl, G. (1998) · Nature · doi:10.1038/35154 · Cited by 1,735
Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based Cohort
Frøslie, K. F., Jahnsen, J., Moum, B. A., & Vatn, M. H. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.051 · Cited by 1,121
Cited by
A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease
Saeid Seyedian, S., Alimentary Tract Research Center, A. J. U. O. M. S., Nokhostin, F., Faculty of Medicine, A. J. U. O. M. S., Forogh Nokhostin, A. P. O. I. M., Dargahi Malamir, M., & Faculty of Medicine, M. D. O. I. M. (2019) · Journal of Medicine and Life · doi:10.25122/jml-2018-0075 · Cited by 817
Turner, D., Levine, A., Escher, J. C., Griffiths, A. M., Russell, R. K., Dignass, A., Dias, J. A., Bronsky, J., Braegger, C. P., Cucchiara, S., et al. (2012) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e3182662233 · Cited by 382
A review on 5-aminosalicylic acid colon-targeted oral drug delivery systems
Shahdadi Sardo, H., Saremnejad, F., Bagheri, S., Akhgari, A., Afrasiabi Garekani, H., & Sadeghi, F. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.01.022 · Cited by 126
Casado-Bedmar, M., & Viennois, E. (2022) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab223 · Cited by 77
Mokhtar, N. M., Nawawi, K. N. M., Verasingam, J., Zhiqin, W., Sagap, I., Azman, Z. A. M., Mazlan, L., Hamid, H. A., Yaacob, N. Y., Rose, I. M., et al. (2019) · BMC Public Health · doi:10.1186/s12889-019-6858-2 · Cited by 55
Metadata
- Authors
- Williams, C., Panaccione, R., Ghosh, S., & Rioux, K.
- Venue
- Therapeutic Advances in Gastroenterology
- Publisher
- SAGE Publications
- Published
- 2011-05-16
- Volume
- 4
- Issue
- 4
- Pages
- 237-248
- ISSN
- 1756-283X (ISSN-L)
- 1756-2848
- OpenAlex
- W2002861309
- Cited by
- 150
- References
- 3
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. https://app.cochat.ai/papers/10.1177/1756283x11405250
- The paper
- Williams, C., Panaccione, R., Ghosh, S., & Rioux, K. (2011). Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. Therapeutic Advances in Gastroenterology. https://doi.org/10.1177/1756283x11405250
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.